Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C

Journal of the Formosan Medical Association

Volumn 115, Issue 4, 2016, Pages 278-283

  Hung, Chao Hung ^a   Hu, Tsung Hui ^a   Lu, Sheng Nan ^a   Chen, Chien Hung ^a   Wang, Jing Houng ^a   Lee, Chuan Mo ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Asia; Hepatitis C; Interferon; Sustained virological response; Vitamin D receptor

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; CALCITRIOL RECEPTOR; VDR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASIAN; CHRONIC HEPATITIS C; CLINICAL FEATURE; DNA POLYMORPHISM; FEMALE; GENE; GENOTYPE; HAPLOTYPE; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VITAMIN D RECEPTOR GENE; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN;

ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HAPLOTYPES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CALCITRIOL; RIBAVIRIN; TAIWAN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84951069175     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2015.11.008     Document Type: Article

References (38)

1. Niederau C., Lange S., Heintges T., Erhardt A., Buschkamp M., Hürter D., et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998, 28:1687-1695.
2. Ikeda K., Saitoh S., Suzuki Y., Kobayashi M., Tsubota A., Koida I., et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998, 28:930-938.
3. Mohd Hanafiah K., Groeger J., Flaxman A.D., Wiersma S.T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57:1333-1342.
4. Pawlotsky J.M., Feld J.J., Zeuzem S., Hoofnagle J.H. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 2015, 62(1 Suppl.):S87-99.
5. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
6. McHutchison J.G., Lawitz E.J., Shiffman M.L., Muir A.J., Galler G.W., McCone J., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593.
7. Kao J.H. Hepatitis C virus infection in Taiwan: past, present, and future. J Formos Med Assoc 2016, 115:65-66.
8. Hung C.H., Lee C.M., Wang J.H., Hu T.H., Chen C.H., Lin C.Y., et al. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer 2011, 128:2344-2352.
9. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
10. Liang C.M., Hu T.H., Lu S.N., Hung C.H., Huang C.M., Wang J.H., et al. Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy. J Viral Hepat 2013, 20:761-769.
11. Hung C.H., Lee C.M., Lu S.N. Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. Expert Rev Anti Infect Ther 2011, 9:525-533.
12. Kau A., Vermehren J., Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008, 49:634-651.
13. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
14. von Essen M.R., Kongsbak M., Schjerling P., Olgaard K., Odum N., Geisler C. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 2010, 11:344-349.
15. Raimondi S., Johansson H., Maisonneuve P., Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009, 30:1170-1180.
16. Petta S., Cammà C., Scazzone C., Tripodo C., Di Marco V., Bono A., et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010, 51:1158-1167.
17. Yokoyama S., Takahashi S., Kawakami Y., Hayes C.N., Kohno H., Kohno H., et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. J Viral Hepat 2014, 21:348-356.
18. Nimer A., Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World J Gastroenterol 2012, 18:800-805.
19. Omori-Mizuno Y., Nakayama N., Inao M., Funyu J., Asabe S., Tomita K., et al. A randomized study comparing vitamin D3 and 1α (OH) D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C. J Gastroenterol Hepatol 2015, 30:1384-1390.
20. Esmat G., El Raziky M., Elsharkawy A., Sabry D., Hassany M., Ahmed A., et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. J Interferon Cytokine Res 2015, 35:49-54.
21. Kitson M.T., Sarrazin C., Toniutto P., Eslick G.D., Roberts S.K. Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis. J Hepatol 2014, 61:1247-1252.
22. Huang Y.W., Liao Y.T., Chen W., Chen C.L., Hu J.T., Liu C.J., et al. Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. Genes Immun 2010, 11:87-93.
23. Vogel A., Strassburg C.P., Manns M.P. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002, 35:126-131.
24. Fan L., Tu X., Zhu Y., Zhou L., Pfeiffer T., Feltens R., et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol 2005, 20:249-255.
25. Lange C.M., Gouttenoire J., Duong F.H., Morikawa K., Heim M.H., Moradpour D. Vitamin D receptor and Jak-STAT signaling crosstalk results in calcitriol-mediated increase of hepatocellular response to IFN-α. J Immunol 2014, 192:6037-6044.
26. Hung C.H., Lu S.N., Wang J.H., Lee C.M., Chen T.M., Tung H.D., et al. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol 2003, 38:153-157.
27. Springer J.E., Cole D.E., Rubin L.A., Cauch-Dudek K., Harewood L., Evrovski J., et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000, 118:145-151.
28. Uitterlinden A.G., Fang Y., Van Meurs J.B., Pols H.A., Van Leeuwen J.P. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004, 338:143-156.
29. Hung C.H., Chiu Y.C., Hu T.H., Chen C.H., Lu S.N., Huang C.M., et al. Significance of vitamin d receptor gene polymorphisms for risk of hepatocellular carcinoma in chronic hepatitis C. Transl Oncol 2014, 7:503-507.
30. Baur K., Mertens J.C., Schmitt J., Iwata R., Stieger B., Frei P., et al. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients. Antivir Ther 2012, 17:541-547.
31. García-Martín E., Agúndez J.A., Maestro M.L., Suárez A., Vidaurreta M., Martínez C., et al. Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C. PLoS ONE 2013, 8:e74764.
32. Hung C.H., Chang K.C., Lu S.N., Wang J.H., Chen C.H., Lee C.M., et al. Spontaneous clearance of hepatitis C virus in an interleukin 28B favorable genotype highly prevalent area. Hepatology 2013, 57:2089-2090.
33. Chuang W.L., Yu M.L. Host factors determining the efficacy of hepatitis C treatment. J Gastroenterol 2013, 48:22-30.
34. Bitetto D., Fattovich G., Fabris C., Ceriani E., Falleti E., Fornasiere E., et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011, 53:1118-1126.
35. Gutiérrez O.M., Farwell W.R., Kermah D., Taylor E.N. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int 2011, 22:1745-1753.
36. Weintraub S.J., Fleckenstein J.F., Marion T.N., Madey M.A., Mahmoudi T.M., Schechtman K.B. Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response. Am J Clin Nutr 2012, 96:1025-1031.
37. Wang T.J., Zhang F., Richards J.B., Kestenbaum B., van Meurs J.B., Berry D., et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010, 376:180-188.
38. Rosen C.J. Clinical practice. Vitamin D insufficiency. N Engl J Med 2011, 364:248-254.